Can machine learning algorithms identify patients at risk of a delay in starting cancer treatment?

Multi-level machine learning models for estimating the risk of delay between cancer diagnosis and treatment initiation in a large group of cancer patients.

CovARC: a streamlined, scalable and accurate COVID-19 risk calculation system

A gamified tool to estimate infection risks associated with day-to-day activities during the COVID-19 pandemic.

August 16, 2023

GSK’s ViiV stops development of Phase 2 HIV antiviral

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 2, 2024

Medacta Group SA reports strong revenue growth at 21.4% at constant currency and adjusted EBITDA margin at 28.2% in the first semester 2023 – Biotech Investments

Medacta Group SA / Key word(s): Half Year Results/Half Year Results 22-Sep-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53

September 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.